乳がんと内分泌療法に関連する更年期症状の女性における治療パターン:米国,英国,ドイツのコホート研究
Mariam Saadedine1, Victoria Banks2, Carina Dinkel-Keuthage2
1Department of Obstetrics and Gynecology, George Washington University, Washington DC.
まとめ
内分泌療法を受けている乳がん患者の更年期症状の治療は,米国,英国,ドイツで非常に低い継続率を示しています. これは,症状管理の選択肢の改善に対する 満たされていない需要を強調しています.
科学分野:
- 腫瘍学
- 薬理学について
- 女性 の 健康
背景:
- 更年期症状は乳がんに対する内分泌療法による一般的な副作用です.
- これらの症状の効果的な管理は,治療の順守と生活の質にとって極めて重要です.
研究 の 目的:
- 閉経症状の治療パターンを調べ,比較する.
- 米国,イギリス,ドイツで乳がんに対する内分泌療法を受けている女性の様々な治療クラスの利用と継続を評価する.
主な方法:
- 米国,イギリス,ドイツの大規模な医療データベースを利用した後見的なコホート研究.
- 2010年から2022年の間に乳がんに対する内分泌療法を受けている18歳から65歳の女性の分析.
- 抗うつ薬,ベンゾジアゼピン,抗薬,抗高血圧薬,ホルモン療法を含む治療クラスの評価
主要な成果:
- 米国では32. 7%,英国では20. 4%,ドイツでは8. 3%が更年期症状の治療に利用された.
- 抗うつ薬はすべての国で最も頻繁な初期治療クラスでした.
- 抗うつ薬の6ヶ月の継続率は著しく低く,42% (米国) から7% (ドイツ) に及び,他の治療法はさらに低い順位を示した.
結論:
- 乳がん患者における更年期症状に対する既存の治療の継続率は非常に低い.
- この集団に対して安全で効果的で 耐性のある治療法の開発に 明確な需要があります
- 新規の治療戦略に関するさらなる研究は,症状の管理と患者のアウトカムを改善するために正当化されています.
さらに関連する動画
関連する概念動画
Menopause
248
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
248
Disorders of the Female Reproductive System
487
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
487
Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Hormonal Regulation of the Menstrual Cycle
688
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
688
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
The Menstrual Cycle
1.4K
The menstrual cycle is a recurrent sequence of changes in the uterine endometrium, specifically its functional layer, the stratum functionalis. This cycle prepares the uterus for potential pregnancy. This cycle typically spans 21–35 days, averaging 28 days, and aligns with the ovarian cycle, regulated by fluctuating levels of ovarian hormones, primarily estrogen and progesterone.
The menstrual phase occurs from days 1 to 5 and involves the shedding of the stratum functionalis, as a...
The menstrual phase occurs from days 1 to 5 and involves the shedding of the stratum functionalis, as a...
1.4K


